ERBB2 and breast carcinoma: In the treatment of breast cancer patients with metastasis, trastuzumab is administered in patients with HER2-overexpressed tumors, which are defined by strong and complete membranous staining of more than 10% of cells in immunohistochemistry (IHC 3+) and/or in situ hybridization (ISH)-amplified [6].